While the Alzheimer's field waits for the FDA's decision on the investigational treatment aducanumab, drug developer Biogen has provided details and endpoints of EMBARK, the drug's ongoing phase IIIb ...
LUND, Sweden, Oct. 7, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ STOCKHOLM: HNSA), today announced positive results from a 12-month follow up analysis from the NICE-01 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results